Clinical Trial Recruiting patient

Clinical Trial Recruiting patient

Recruiting Patients in Ongoing Studies Contact Detail: +91-9983656667, +91-9828683771, +91-9414362711 e-mail: bmchrcclinicaltrial@gmail.com whatsup No. +91-9829014996

No. Ongoing Studies Principal Investigator Since Dated
1 A prospective, multicenter, open label single arm Phase IV clinical trial to assess safety of ImbruvicaTM (Ibrutinib capsules 140 mg) in Indian patients with chronic lymphocytic leukemia or mantle cell lymphoma who have received at least one prior therapy or chronic lymphocytic leukemia with 17p deletion Dr. Naresh Somani
2 Ref: Protocol: 0063-17_ A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy Dr. Naresh Somani
3 Ref:A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1). Dr. Naresh Somani
4 A randomised, double-blind, parallel group, equivalence, multicenter phase III trial to compare the efficacy, safety, pharmacokinetics and immunogenicity of HD204 to Avastin® in patients with metastatic or recurrent non-squamous non-small cell lung cancer? SAMSON-II Dr. Naresh Somani
5 Protocol Title : ?A Prospective, Randomized, Multicentre, Comparative, open-label, Parallel study to evaluate the Efficacy, Safety and Pharmacokinetics of Test-Trastuzumab Emtansine (ZRC-3255; Cadila Healthcare Ltd) and Reference-Trastuzumab Emtansine (Kadcyla@, a product of Roche) in HER2- Positive Metastic Breast Cancer Patients Dr. Naresh Somani
6 ?A pilot study (Phase II Trial )of Gefitinib With Pemetrexed as First-Line Therapy in Patients With Advanced Non-squamous Non?Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations positive patients.? Dr. Naresh Somani
7 Protocol ALN-AT3SC-003: ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX Dr. Upendra Sharma
8 Ref: ALN-AT3SC-004 A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX. Dr. Upendra Sharma
9 A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease Dr. Lalit Mohan Sharma
10 Title of study: Bayer 21140 – A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC) Dr. Pawan Agarwal Mar-2021
11 Protocol ID: A5481145 Version 1.0 Dated 19 OCT 2020 Protocol Title: “Treatment patterns and clinical outcomes among Indian patients receiving Palbociclib combinations for HR+/HER2- Advanced/Metastatic breast cancer in real world settings Dr. Ajay Bapna April 2021
12 A prospective, multicenter, open label single arm Phase IV clinical trial to assess safety of ImbruvicaTM (Ibrutinib capsules 140 mg) in Indian patients with chronic lymphocytic leukemia or mantle cell lymphoma who have received at least one prior therapy or chronic lymphocytic leukemia with 17p deletion Dr. Upendra Sharma Dec-2019
13 Protocol LEE011A2207 Ref: A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease Dr. Ajay Bapna Jan-2020
14 Ref No. “An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease CLEE011A2404. Dr. Ajay Bapna Oct-2019
15 Ref:A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1). Dr. Aseem K Samar Oct-2019